Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

[Preprint]. 2023 Apr 25:2023.04.20.23288534. [Version 1] doi: 10.1101/2023.04.20.23288534

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

PMC Copyright notice

Fig. 4: — AIM-NASH models were deployed on WSIs from baseline and week 48 biopsies from patients enrolled in the phase 2b ATLAS trial, which evaluated combination therapies for individuals with advanced NASH fibrosis. (a) For the trial endpoint NAS ≥ 2-point improvement, fibrosis improvement without worsening of NASH, and NASH resolution without worsening of fibrosis, AIM-NASH models showed a greater proportion of responders compared with that determined by the trial central reader. Sample sizes varied depending on data availability. (b) The placebo-adjusted response rate detected by AIM-NASH was greater than that detected by the central reader.

AI, artificial intelligence; AIM, artificial intelligence-based measurement; NAS, nonalcoholic fatty liver disease activity score; NASH, nonalcoholic steatohepatitis; WSI, whole slide image.